Genetic Technologies partnership with CancerlQ

Genetic Technologies Limited (ASX:GTG) has announced a partnership agreement with Chicago based CancerlQ, a move that will expand the company's clinical risk prediction capabilities and provide access to over 45 healthcare systems and 250 clinics in the US. The partnership will enable Genetic Technologies to integrate its geneType Risk Assessment Test portfolio into CancerlQ's platform, allowing healthcare providers to assess patients' comprehensive risk and personalize cancer prevention efforts.

Executive Commentary on Partnership

GTG's Chairman, Peter Rubinstein, expressed excitement about the partnership, stating, 'We are very excited to have been invited to become part of the CancerIQ platform to be implemented upon completing our current capital raise. This approach will make the geneType Risk Assessment Tests more easily accessible to the clinical community. We look forward to the co-marketing opportunities with CancerIQ to increase the awareness of population risk-assessment. We are confident in the value of this population healthcare approach, ultimately providing the opportunity to improve the health outcomes for people generally.'

Summary of Genetic Technologies and CancerlQ Partnership

Genetic Technologies' partnership with CancerlQ marks a significant step in expanding its clinical risk prediction capabilities and reaching a wider network of healthcare systems and clinics in the US. The integration of geneType Risk Assessment Test portfolio into CancerlQ's platform will enable healthcare providers to personalize cancer prevention efforts and assess patients' comprehensive risk. This strategic move aligns with Genetic Technologies' commitment to improving health outcomes through population healthcare approach. The partnership is expected to enhance the visibility of geneType within the US healthcare systems and streamline the test ordering experience for practitioners and patients. Genetic Technologies' focus on population healthcare and CancerlQ's demonstrated level of adoption in clinical settings position the partnership for success in improving healthcare outcomes for individuals.